绥美凯应怎么服用？

Inbec (Inbec) is a treatment plan that uses DTG, an integrase inhibitor, as the core drug, and is combined with two core drugs, abacavir and lamivudine. It is made into a single tablet and promoted, making the core drug a great improvement in HAART treatment.

Medication Guide for Suimeikai (Domitabalamid Tablets, Inbec):

Trimax (dolutegravir, Inbec) is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine can be used. In these cases, physicians should refer to the respective product information for these drugs.

Recommended dosage: Adults and adolescents (weighing at least 40 kg): For adults and adolescents, the recommended dosage of Sumeika is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. 

If a dose is missed: If the patient misses a dose of Suimei Kai, and there are more than 4 hours before the next dose, Sui Mei Kai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

Geriatric patients: There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged 65 years and older, and there is no evidence that older patients require different doses than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group. 

Patients with renal impairment: Patients with a creatinine clearance rate less than 50 mL/min are not recommended to take Suimeike (Dolutea Paramide Tablets, Inbec). 

Patients with hepatic impairment: Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment; therefore, the use of Inbec is not recommended unless deemed necessary. For patients with mild hepatic impairment, close monitoring is required, including monitoring of abacavir plasma levels when feasible.

The above is the method of taking Suimeicai (Inbec) provided by our Medical Companion Travel Overseas Medical Consulting Service Company. Patients must read it carefully and use the medicine with caution.